Why the study?
HFpEF is a heterogeneous clinical syndrome influenced by multiple comorbidities, warranting a tailored phenotype-based therapeutic approach to optimize clinical outcomes.
This scientific statement provides a structured algorithm for phenotyping HFpEF patients to guide personalized therapy beyond foundational SGLT2 inhibitors.
Answers are grounded in this paper and cite their sources.
Provides clinicians a phenotype-based HFpEF treatment algorithm; extends guidelines by integrating comorbidities and polypharmacy.
Heart failure with preserved ejection fraction (HFpEF) represents a highly heterogeneous clinical syndrome affected in its development and progression by many comorbidities. The left ventricular diastolic dysfunction may be a manifestation of various combinations of cardiovascular, metabolic, pulmonary, renal, and geriatric conditions. Thus, in addition to treatment with sodium-glucose cotransporter 2 inhibitors in all patients, the most effective method of improving clinical outcomes may be therapy tailored to each patient's clinical profile. To better outline a phenotype-based approach for the treatment of HFpEF, in this joint position paper, the Heart Failure Association of the European Society of Cardiology, the European Heart Rhythm Association and the European Hypertension Society, have developed an algorithm to identify the most common HFpEF phenotypes and identify the evidence-based treatment strategy for each, while taking into account the complexities of multiple comorbidities and polypharmacy.
No takes yet. Share an insight, caveat, or question.
Anker et al. (2023) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: